Results 261 to 270 of about 1,610,988 (356)

Trends and future predictions of chronic kidney disease due to diabetes mellitus type 2 attributable to dietary risks: insights based on GBD 2021 data. [PDF]

Front Nutr
Xu M, Wei H, Lv D, Wei Y, Liu Z, Zhang Y, Liu Y.   +6 more
europepmc   +1 more source

Review of: "Dermatoglyphics: The Future of Screening Type 2 Diabetes Mellitus?" [PDF]

Amara Andleeb
openalex   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Effectiveness and safety of combining thiazides with loop diuretics vs. loop diuretics monotherapy in patients with acute decompensated heart failure: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aims This study investigated factors associated with and outcomes of combined loop diuretics with hydrochlorothiazide (HCTZ) for acute decompensated heart failure (ADHF). Methods In this retrospective study, adults hospitalized for ADHF and who received intravenous loop diuretics between January 2016 and March 2023 were enrolled.
Chia‐Chen Hsu, Hsien‐Chih Chiu, Ju‐Chieh Wung, Yueh‐Ching Chou, Yuh‐Lih Chang, Chian‐Ying Chou, Chin‐Chou Huang   +6 more
wiley   +1 more source

Original paper
Selected antioxidative enzyme activities in patients with diabetes mellitus type 2

, 2005
Robert Błaszczak, Józef Kędziora, Danuta Ertel, Maciej Rutkowski, Kornelia Kędziora–Kornatowska, Tomasz Kornatowski, Jacek Rysz, Krzysztof Kujawski, Danuta Stachura   +8 more
openalex   +1 more source

Correction: Kovner et al. Liver Fluke-Derived Molecules Accelerate Skin Repair Processes in a Mouse Model of Type 2 Diabetes Mellitus. Int. J. Mol. Sci. 2024, 25, 12002 [PDF]

А. В. Ковнер, Yaroslav Kapushchak, Oxana Zaparina, Dmitry Ponomarev, Maria Y. Pakharukova   +4 more
openalex   +1 more source

Why and how do we perform physical examination(s) in clinical trials? A use case of drug intervention trials in type 2 diabetes mellitus

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of this study was to determine the purpose and use of physical examination (PE) in phase 3 and 4 drug interventional clinical trials within type 2 diabetes mellitus. Methods A total of 226 clinical trial protocols identified from the ClinicalTrials.gov database were systematically reviewed by five researchers.
Julia Kopanz, Amy Rogers, Lina Pérez‐Breva, Emily Hall, Prashasthi Devaiah, Isla S. Mackenzie, Bart Lagerwaard, Diederick E. Grobbee, Mira G. P. Zuidgeest, on behalf of the Trials@Home consortium   +9 more
wiley   +1 more source

Nutrient patterns and risk of diabetes mellitus type 2: a case-control study. [PDF]

BMC Endocr Disord
Haramshahi M, A-Elgadir TME, Daabo HMA, Altinkaynak Y, Hjazi A, Hjazi A, Saxena A, Najm MAA, Almulla AF, Alsaalamy A, Kashani MA.   +10 more
europepmc   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source